Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Learning Objectives

We aim to cover the following topics:

  1. The rationale for targeting DDR, including PARP inhibition as the proof of concept.
    • The mechanism of action of PARP inhibitors.
    • Role of diagnostics, and how diagnostics ensure appropriate patient selection.
  2. Current role of PARP inhibition in clinical practice, including:
    • The efficacy and safety/tolerability profile of PARP inhibitors.
    • The potential benefit of PARP inhibitors in various tumour types.
    • The appropriate patient selection for PARP inhibition.
    • The current indications for PARP inhibition in clinical practice.
  3. Anticipate the potential future application of targeting DDR in clinical practice, including
    • The potential combination strategies with PARP inhibitors.
    • The potential future role of targeting DDR in clinical practice, including drugs with a novel mode of action and their potential combination strategies.
    • The potential future indications for targeting DDR and PARP inhibition and the rationale for targeting DDR in these indications.
    • The potential future role of diagnostics in DDR.

PARP inhibitors

DNA Damage Response

Information for Patients and Caregivers

Module 1 provides an introduction to PARP inhibitors

Module 2 provides an overview of the DDR pathway in health and disease, including cancer.

Information on cancer drugs known as DDR (DNA damage response)-targeting agents and PARP (poly-ADP ribose polymerase) inhibitors

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings